MPO and neoplasm: While improved immunotherapy outcomes have been observed by decreasing the infiltration of myeloid cells into the PDAC tumor microenvironment [38–40], our studies demonstrate that by targeting MPO, we both enhance ICT efficacy and also limit immunosuppression in myeloid cells.